Navigation Links
Study Validates Clinical Accuracy of 50% Dose Reduction for Positron Emission Mammography
Date:6/7/2011

SAN ANTONIO, June 7, 2011 /PRNewswire/ -- Presented today at the Society of Nuclear Medicine 2011 Annual Meeting researchers from Swedish Medical Center and the University of Washington showed that FDG dose for Positron Emission Mammography (PEM) may be reduced by at least 50% without altering image quality.

PEM is the breast application of the Naviscan high-resolution PET scanner showing the location as well as the metabolic phase of a lesion.  The metabolic view assists physicians in making the optimal cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term "specificity."  PEM is different than x-ray mammography in that it is currently not used as a screening modality, rather is deployed to confirm extent of disease and aid in treatment planning in a patient already diagnosed with a primary breast cancer.

"With our limited clinical experience with invasive ductal carcinomas to date the clinical diagnostic quality of images appear equivalent between the 5 millicurie (mCi) dose and the traditional 10 millicurie dose. However the longer uptake time (90-120 minutes) we believe significantly improves lesion to background ratio with our invasive ductal carcinomas," stated Dr. James Rogers, a nuclear medicine physician at Seattle Nuclear Medicine and co-author of the study. "The tradeoff between lowering dose and minimally increasing imaging scan time from a 7 to 10 minute scan appears to be a reasonable imaging strategy. We are still formulating our opinion and strategy in regard to lower FDG doses that are less than 5 millicuries, and are hopeful that an individualized patient strategy based on patient weight will allow us to show that lower FDG doses will be possible for a large number of our patients.  We have not done enough DCIS only patients or Invasive Lobular patients to make a conclusion at this time."

The researchers presented results of a study to detect lesions with very low doses of radiation using the Naviscan high-resolution PET scanner.  Preliminary results from five patients with invasive ductal carcinoma as well as phantom images show that PEM lesion detection at a 5 mCi injected dose of FDG, or 50% lower than the dose commonly used in clinical practice, yielded comparable sensitivity while maintaining lesion detectability.  Preliminary results also revealed that injected dose could be reduced further for lighter patients or with concordant increased scan time. These results are part of an ongoing clinical trial at Swedish Medical Center with the goal of determining the lowest optimized dose levels of FDG required to produce high quality PEM images in patients with breast cancer.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.

For more information, including images, videos, quotes and links, please visit the social media news release (SMNR) at http://pitch.pe/151545.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Finds Patient Adherence to Statin Medications Reduces Hospitalizations and Healthcare Costs
2. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
3. New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
4. Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
5. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
6. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
7. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
8. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
9. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
10. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
11. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... LG Innotek today announced that the company has developed the world,s ... is 1.5 times higher than the competitor,s 45mW module. ... of 200 -- 280nm, allowing it to be used for sterilization purpose. ... Innotek,s product emits UV in the range of 280nm. ... Until now, UV-C LED has ...
(Date:2/23/2017)... Mass. , Feb. 23, 2017   ... partner to global in vitro diagnostics manufacturers and ... series titled "Catalyzing Implementation of NGS-Based Tests" to ... March 30, 2017 at 11am Eastern Standard Time ... is to highlight the need for improved performance ...
(Date:2/23/2017)... , Feb. 23, 2017  Spheryx, ... one poster presentation at PittCon 2017 Conference ... Pittcon is the world,s largest annual premier ... serves a wide array of industry, academic ... discovery and QA, food safety, environmental, bioterrorism ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... CALNOC, the nation’s first and only nursing quality indicators ... – Empowerment, Value and Collaboration – in Seattle, WA on October 23, 2017. , ... Health System in Seattle since 2000. In addition to his role at Virginia Mason, ...
(Date:2/23/2017)... ... 23, 2017 , ... Thomas Vas-Don suffered from severe injury due ... was able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ... the principals of massage, anatomy , trigger points and referral pain patterns ...
(Date:2/22/2017)... ... ... Gevir, a New Zealand-based company that focuses on developing powder and capsule ... Amazon.com, the world’s largest online retailer. , The company was founded in ... treatment for Shelley’s Multiple Sclerosis, which she’d been diagnosed with at 28 years old. ...
(Date:2/22/2017)... ... 2017 , ... The National Academy of Certified Care Managers ... 2017 testing period. NACCM, a nonprofit organization, has provided the premier certification for ... periodically re-calibrated to ensure that newly certified professionals are prepared to work effectively ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... adults with chronic conditions reported skipping doses or not filling a prescription because ... or under-insured, rates of cost-related problems getting medications were 30-60%*. At ...
Breaking Medicine News(10 mins):